Significance of TP53 mutations as predictive markers of adjuvant cisplatin‐based chemotherapy in completely resected non‐small‐cell lung cancer
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Adjuvant cisplatin‐based chemotherapy only marginally improves survival in patients with completely resected non‐small‐cell lung cancer (NSCLC). We have evaluated the predictive value of mutations in TP53, encoding the tumour suppressor p53, in the International Adjuvant Lung Cancer Trial (IALT), a randomized trial of adjuvant cisplatin‐based chemotherapy against observation. TP53 (exons 4–8) was sequenced in 524 archived specimens of IALT patients with a median follow‐up of 7.5 years. Predictive analyses were based on Cox models adjusted for clinical and pathological variables. P‐values ≤0.01 were considered as significant. Mutations were detected in 221 patients (42%) and had no predictive value for the effect of chemotherapy (interaction between TP53 and treatment: p = 0.17 for Overall Survival (OS); p = 0.06 for Disease‐Free Interval, (DFS)). However, among patients with mutations, outcome appeared worse in treatment compared to observation arms (HR for OS = 1.36 (95% CI [0.97–1.31), p = 0.08; DFS = 1.40 (95% CI [1.01–1.95]), p = 0.04). When grouping mutations into classes according to predicted effects on protein structure, the tendency towards worse outcomes was restricted to “structure” mutations affecting residues of the hydrophobic core that are not located at the p53 protein‐DNA interface (HR for death in this class vs wild‐type T53 = 1.66; 95% CI [1.10–2.52], p = 0.02). Overall, TP53 mutations are not significant predictors of outcome in this trial of cisplatin‐based chemotherapy, although a specific class of structural mutations may be associated with a tendency towards worse outcomes upon treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642
Self-citationTP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes
Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210302 · Cited by 884
Self-citation
Cited by
Shepherd, F. A., Lacas, B., Le Teuff, G., Hainaut, P., Jänne, P. A., Pignon, J.-P., Le Chevalier, T., Seymour, L., Douillard, J.-Y., Graziano, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.2893 · Cited by 124
“Full laboratory methods have been published previously.(11,15,27)”
Self-citationDeben, C., Wouters, A., de Beeck, K. O., van Den Bossche, J., Jacobs, J., Zwaenepoel, K., Peeters, M., Van Meerbeeck, J., Lardon, F., Rolfo, C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4433 · Cited by 73
“In addition, TP53 mutations seem to negatively influence the response to CDDP therapy as a significant better overall survival and response rate was observed in TP53 wild type patients compared to TP53 mutant patients [19-21].”
Result
Metadata
- Authors
- Ma, X., Rousseau, V., Sun, H., Lantuejoul, S., Filipits, M., Pirker, R., Popper, H., Mendiboure, J., Vataire, A.-L., Le Chevalier, T., Soria, J. C., Brambilla, E., Dunant, A., & Hainaut, P.
- Venue
- Molecular Oncology
- Publisher
- Wiley
- Published
- 2014-01-15
- Volume
- 8
- Issue
- 3
- Pages
- 555-564
- ISSN
- 1574-7891 (ISSN-L)
- 1878-0261
- OpenAlex
- W2018617116
- Cited by
- 42
- References
- 2
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Significance of TP53 mutations as predictive markers of adjuvant cisplatin‐based chemotherapy in completely resected non‐small‐cell lung cancer. https://app.cochat.ai/papers/10.1016/j.molonc.2013.12.015
- The paper
- Ma, X., Rousseau, V., Sun, H., Lantuejoul, S., Filipits, M., Pirker, R., Popper, H., Mendiboure, J., Vataire, A.-L., Le Chevalier, T., Soria, J. C., Brambilla, E., Dunant, A., & Hainaut, P. (2014). Significance of TP53 mutations as predictive markers of adjuvant cisplatin‐based chemotherapy in completely resected non‐small‐cell lung cancer. Molecular Oncology. https://doi.org/10.1016/j.molonc.2013.12.015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.